Product nameHuman beta IG H3 Matched Antibody Pair Kit
See all TGFBI kits
Assay typeELISA set
Range31.25 pg/ml - 2000 pg/ml
Species reactivityReacts with: Human
Matched Antibody Pair Kits include a capture and a biotinylated detector antibody pair, along with a calibrated protein standard, suitable for sandwich ELISA. The Matched Antibody Pair Kit can be used to quantify native and recombinant human IG H3 (TGFBI).
Matched antibody pair kits and reagents deliver consistent, specific, and sensitive results.
• Batch-to-batch consistency: only recombinant monoclonal antibodies are used in our matched antibody pairs.
• Specificity: antibody pairs are screened in plasma and serum to ensure specificity in complex samples.
• Sensitivity: benchmarked against commercially available antibody pairs to ensure equivalent or superior performance compared with the competition.
Additional buffers and plates are required for the assay. An accessory pack can be purchased which includes buffer reagents required to perform 10 x 96-well plate sandwich ELISAs (ab210905).
To receive an electronic copy of the Certificate of Analysis, please send an email with "CoA for matched antibody pair kit" in the subject line and the desired product number and lot number in the body of the email.
Tested applicationsSuitable for: ELISAmore details
Storage instructionsStore at -20°C. Please refer to protocols.
Components 10 x 96 tests 2 x 96 tests Human beta IG-H3 Capture Antibody 1 x 100µg 1 x 20µg Human beta IG-H3 Detector Antibody 1 x 25µg 1 x 5µg Human beta IG-H3 Lyophilized Protein 1 vial 1 vial
FunctionBinds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation.
Tissue specificityHighly expressed in the corneal epithelium.
Involvement in diseaseDefects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD) [MIM:121820]; also known as Cogan corneal dystrophy or map-dot-fingerprint type corneal dystrophy. EBMD is a bilateral anterior corneal dystrophy characterized by grayish epithelial fingerprint lines, geographic map-like lines, and dots (or microcysts) on slit-lamp examination. Pathologic studies show abnormal, redundant basement membrane and intraepithelial lacunae filled with cellular debris. Although this disorder usually is not considered to be inherited, families with autosomal dominant inheritance have been identified.
Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1) [MIM:121900]; also known as corneal dystrophy granular type. Inheritance is autosomal dominant. Corneal dystrophies show progressive opacification of the cornea leading to severe visual handicap.
Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1) [MIM:122200]. Inheritance is autosomal dominant.
Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB) [MIM:602082]; also known as corneal dystrophy of Bowman layer type 2 (CDB2).
Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB) [MIM:608470]; also known as corneal dystrophy of Bowman layer type 1 (CDB1).
Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A) [MIM:608471]. CDL3A clinically resembles to lattice corneal dystrophy type 3, but differs in that its age of onset is 70 to 90 years. It has an autosomal dominant inheritance pattern.
Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD) [MIM:607541]. ACD could be considered a variant of granular dystrophy with a significant amyloidogenic tendency. Inheritance is autosomal dominant.
Sequence similaritiesContains 1 EMI domain.
Contains 4 FAS1 domains.
modificationsGamma-carboxyglutamate residues are formed by vitamin K dependent carboxylation. These residues are essential for the binding of calcium.
Cellular localizationSecreted > extracellular space > extracellular matrix. May be associated both with microfibrils and with the cell surface.
- Information by UniProt
- RGD containing collagen associated protein
Our Abpromise guarantee covers the use of ab220132 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
ab220132 has not yet been referenced specifically in any publications.